| |
Article Title |
Author(s) |
Pages |
|
|
|
Masthead
|
|
IFC
|
|
|
|
The Evolving Role of Bendamustine in Lymphoid Malignancy: Understanding the Drug and Its Mechanism of Action—Introduction
Chemotherapy is the cornerstone of current treatment strategies for many hematologic malignancies, including most indolent B-cell malignancies such as chronic lymphocytic leukemia (CLL), follicular ly...
|
Lorenzo M. Leoni
|
S1-S3
|
|
|
|
Bendamustine: Rescue of an Effective Antineoplastic Agent From the Mid-Twentieth Century
Although the alkylating agent bendamustine was developed in Germany in the mid-twentieth century, it has only recently come to the forefront in the rest of the world as an effective chemotherapeutic a...
|
Lorenzo M. Leoni
|
S4-S11
|
|
|
|
Mechanism of Action: The Unique Pattern of Bendamustine-Induced Cytotoxicity
Bendamustine has demonstrated substantial efficacy in the treatment of hematologic malignancies and continues to distinguish itself from other alkylating agents with regard to its activity in tumor ce...
|
Lorenzo M. Leoni,
John A. Hartley
|
S12-S23
|
|
|
|
Bendamustine's Emerging Role in the Management of Lymphoid Malignancies
The potent alkylating agent bendamustine has demonstrated substantial efficacy in patients with non-Hodgkin lymphomas (NHLs), including chronic lymphocytic leukemia (CLL), follicular lymphoma, and man...
|
Mathias J. Rummel,
Stephanie A. Gregory
|
S24-S36
|
|
|
|
Conclusion and Future Directions
Bendamustine is a bifunctional mechlorethamine derivative that shares similarities to other alkylators; however, the presence of a benzimidazole ring may confer “nucleoside-like” properties and may al...
|
Lorenzo M. Leoni
|
S37-S38
|
|
| Frontmatter |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Table of Contents
|
|
A1
|
|
|
|
Supplement Sponsorship
|
|
A2
|
|
|
|
Faculty Disclosure
|
|
A3
|
|
